UNVC/11Three: Where are the OTC Disclosures & FDA NDA Filings? When you look closely at the marketing materials for 11Three and RELIEFTA™, 11Three’s official workflow graphic explicitly cites "Univec’s FDA labeler and PLD infrastructure, direct eDRLS listing, and Dispense-Doc point-of-care billing." If UNVC’s infrastructure is central to this commercial pipeline, why are there zero disclosed licensing contracts, material terms, or revenue-sharing agreements in UNVC’s OTC Markets filings?
This information is all from the 2-year website of- Updated date 2024-10-04 13:59:11-Creation date-2024-10-04 13:59:11-Registry expiry date-2027-10-04 13:59:11 https://11threetech.com/
I hinted to investors this partnership was coming in March of this year, lot of my post seem to disappear.
PL
This information is all from the 2-year website of- Updated date 2024-10-04 13:59:11-Creation date-2024-10-04 13:59:11-Registry expiry date-2027-10-04 13:59:11 https://11threetech.com/
Look closely at this screenshot-The product mockups display 5% Lidocaine labeled "Rx Only" (LOT RFT250501-EXP-2027-05). If this commercial relationship and product pipeline have been actively solicited to prospective partners and investors, what I don't understand is why has none of this been substantiated in formal OTC Markets disclosures?Quote:Commercialization & Infrastructure
From Formulation to Point-of-Care
11Three combines SENDS™ formulation technology with cGMP manufacturing, Univec’s FDA labeler and PLD infrastructure, direct eDRLS listing, and DispenseDoc point-of-care billing to create a streamlined commercialization pathway for selected products.
I hinted to investors this partnership was coming in March of this year, lot of my post seem to disappear.
PL
3
1
